Duarte Rafael F, Labopin Myriam, Bader Peter, Basak Grzegorz W, Bonini Chiara, Chabannon Christian, Corbacioglu Selim, Dreger Peter, Dufour Carlo, Gennery Andrew R, Kuball Jürgen, Lankester Arjan C, Lanza Francesco, Montoto Silvia, Nagler Arnon, Peffault de Latour Régis, Snowden John A, Styczynski Jan, Yakoub-Agha Ibrahim, Kröger Nicolaus, Mohty Mohamad
Hospital Universitario Puerta de Hierro Majadahonda - Universidad Autónoma de Madrid, Madrid, Spain.
EBMT Paris Study Office, Hopital Saint Antoine, Paris, France.
Bone Marrow Transplant. 2019 Oct;54(10):1525-1552. doi: 10.1038/s41409-019-0516-2. Epub 2019 Apr 5.
This is the seventh special EBMT report on the indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on transplant indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered together with the risk of the disease, the risk of the transplant procedure and the results of non-transplant strategies. In over two decades since the first report, the EBMT indications manuscripts have incorporated changes in transplant practice coming from scientific and technical developments in the field. In this same period, the establishment of JACIE accreditation has promoted high quality and led to improved outcomes of patient and donor care and laboratory performance in transplantation and cellular therapy. An updated report with operating definitions, revised indications and an additional set of data with overall survival at 1 year and non-relapse mortality at day 100 after transplant in the commonest standard-of-care indications is presented. Additional efforts are currently underway to enable EBMT member centres to benchmark their risk-adapted outcomes as part of the Registry upgrade Project 2020 against national and/or international outcome data.
这是欧洲血液与骨髓移植协会（EBMT）关于血液系统疾病、实体瘤和免疫紊乱的造血干细胞移植适应证的第七份特别报告。我们的目的是根据EBMT成员国和中心当前的临床实践，提供有关移植适应证的一般指导。为了帮助患者做出决策，这些建议必须与疾病风险、移植手术风险以及非移植策略的结果一并考虑。自第一份报告发布二十多年来，EBMT适应证手册纳入了该领域科技发展带来的移植实践变化。同一时期，国际细胞治疗认证联合委员会（JACIE）认证的建立推动了高质量发展，并改善了移植和细胞治疗中患者及供体护理以及实验室表现的结果。本文呈现了一份更新报告，其中包含操作定义、修订后的适应证以及一组额外数据，这些数据涉及最常见的标准治疗适应证下移植后1年的总生存率和第100天的非复发死亡率。目前正在做出额外努力，以使EBMT成员中心能够将其风险适应性结果作为2020年注册升级项目的一部分，与国家和/或国际结果数据进行基准对比。
